Casirivimab – Imdevimab for patients with mild COVID-19

This recommendation applies to acute COVID-19 in adults. Some of our recommendations vary according to the severity of COVID-19 illness. Definitions of the categories are based on the World Health Organization (WHO) criteria and can be viewed by clicking the plus (+) signs below.

RECOMMENDATION:

We do not recommend Casirivimab and Imdevimab (REGEN-COV™️) for people with mild COVID-19 infection and no risk factors for progression to severe disease due to the involved expense and low likelihood of progression to severe disease. However, Casirivimab and Imdevimab (REGEN- COV™️) may be given in people with mild COVID-19 infection with one or more risk factors (see list below) to prevent progression to severe disease within the first ten days of the illness, irrespective of antibody status.

DATE OF RECOMMENDATION: 10/08/2021